In a city where public health headlines usually range from grim to grimmer, here's a genuinely good story: San Francisco's STI rates are dropping, and it's not by accident.

The key driver? A preventive antibiotic-treatment strategy — known as doxy-PEP (doxycycline post-exposure prophylaxis) — that's helping reduce cases of syphilis, gonorrhea, and chlamydia across the city. The approach is straightforward: rather than waiting for infections to take hold and then treating them, high-risk individuals take a dose of doxycycline after potential exposure. The results have been meaningful and measurable.

This is the kind of public health intervention that should make everyone — regardless of political persuasion — sit up and pay attention. It's targeted, it's cost-effective, and it actually works. Treating STIs after they spread is expensive. Emergency room visits, complications from untreated syphilis, and the downstream costs of chronic infection burden both individuals and the public health system. Prevention on the front end is simply smarter fiscal policy.

San Francisco has long been a pioneer in harm-reduction strategies, and not all of them have panned out. The city's track record on drug policy, for instance, has been a case study in good intentions producing questionable outcomes. But doxy-PEP is different. It's backed by clinical evidence, it empowers individuals to take control of their own health, and it doesn't require building another layer of bureaucracy to administer.

There's a lesson here for city leaders who are perpetually drawn to expensive, top-down programs: sometimes the most effective intervention is giving people the tools to protect themselves and getting out of the way. No new department. No bloated budget line item. Just science, individual responsibility, and pragmatic policy working together.

We'll take the win. San Francisco could use more of them.